Cornea
Share your love
Porter Ophthalmology Clarifies Long-Term Vision Planning for LASIK Patients Considering Cataract Surgery
Raleigh, NC – October 27, 2025 – PRESSADVANTAGE – With millions of Americans having undergone LASIK vision correction in the past three decades, a growing number are now approaching the age where cataract surgery becomes a consideration. Porter Ophthalmology, a…
Precision strategy: Optimizing visual outcomes with advanced small-aperture lenses | Ophthalmology Times
(Image Credit: AdobeStock/Wirestock) A recent Ophthalmology Times Case-Based Roundtable addressed the pathway to achieving optimized visual outcomes using an advanced small-aperture IOL (IC-8 Apthera; Bausch + Lomb Surgical). Mark Lobanoff, MD, an ophthalmologist in St Louis Park, Minnesota, shared the highlights…
Novel therapy for incision-free keratoconus: Q&A with Gloria B. Chiu, OD, FAAO, FSLS | Ophthalmology Times
The FDA-approved, incision-free Epioxa therapy is changing the landscape of keratoconus care, explains Gloria B. Chiu, OD, FAAO, FSLS. (Image credit: AdobeStock/Zarina Lukash) Glaukos recently obtained FDA clearance for Epioxa, a topical, incision-free therapy for keratoconus that preserves the corneal epithelium.1 The…
Aurion Biotech releases positive 12-month results from phase 1/2 CLARA trial | Ophthalmology Times
(Image Credit: AdobeStock/tonstock) Aurion Biotech has released positive 12-month results from its phase 1/2 CLARA trial evaluating the safety, efficacy, and tolerability of AURN001 in patients with corneal edema secondary to corneal endothelial dysfunction. In the CLARA trial, a double-masked,…
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus | Ophthalmology Times
Glaukos’ FDA-approved Epioxa topical therapy offers a first-of-its-kind, incision-free treatment for patients with keratoconus, according to the company. Glaukos announced that the FDA has approved the new drug application for its topical drug therapy (Epioxa HD/Epioxa) for keratoconus.1,2 This approval…
Heterogeneous Ocular Biomarkers May Predict Sjögren’s Disease Extraocular Features | Ophthalmology Times
(Image Credit:AdobeStock) A study of the ocular features of Sjogren’s disease reported the heterogeneity of the disorder’s ocular presentations.1 The authors, led by research fellow Drew C. Baeza, MD, and associates, reported “distinct associations between specific dry eye and the…
Lupin signs definitive agreement to acquire VISUfarma | Ophthalmology Times
(Image Credit: AdobeStock/Rido) Lupin’s subsidiary, Nanomi, has signed a definitive agreement to acquire VISUfarma, a portfolio company of GHO Capital Partners LLP. Lupin notes that the acquisition will help the company expand its European business, as well as advance the…
Anniversary of the spectral OCT prototype: 25 years young and growing | Ophthalmology Times
A recent conference celebrated the creation of the first prototype of the spectral optical coherence tomography (SOCT) instrument. Introduced in 2000, the prototype, which was developed at the Institute of Physics of Nicolaus Copernicus University in Toruń, Poland, was the…
Q&A: Boris Stanzel on the use of methotrexate in PVR cases | Ophthalmology Times
Photo of Boris Stanzel, MD, at the 2025 EURETINA meeting Professor Boris Stanzel, MD, presented research on methotrexate’s use in PVR retinal detachment surgery at the 2025 EURETINA congress, which was held in Paris, France. The study of 20 patients…
OKYO Pharma details next clinical stage of urcosimod development | Ophthalmology Times
OKYO Pharma has announced its plans for the next stage of clinical development of urcosimod (formerly OK-101), its lead drug candidate to treat neuropathic corneal pain (NCP). NCP is a condition that causes severe pain and sensitivity of the eyes, face,…